Cytokine Effects on Cell Viability and Death of Prostate Carcinoma Cells
AuthorChondrogiannis, G.; Kastamoulas, M.; Kanavaros, P.; Vartholomatos, G.; Bai, M.; Baltogiannis, D.; Sofikitis, N.; Arvanitis, D.; Galani, V.
We analyzed the effects of IL-13, IFN-gamma, and IL-1 beta on cell viability and death of LNCaP and PC-3 cells and major signaling pathways involved in these effects. Significant increase of LNCaP cell death (apoptotic and necrotic) and increased levels of active caspase 3 were observed in cells treated with inhibitors of ERK 1/2 (UO126) and p38 (SB203580) prior to IL-1 beta treatment in comparison to cells treated with UO126, SB203580, or IL-1 beta alone. Significant increase of LNCaP but not PC-3 cell death was detected after treatment with LY-294002 (inhibitor of phosphatidylinositol 3-kinase). No significant increase of LNCaP and PC-3 cell death was observed after treatment with SP600125 (inhibitor of JNK), SB203580 (inhibitor of p38), UO126 (inhibitor of ERK 1/2), or BAY 11-7082 (inhibitor of NF-kappa B). Reduced c-FLIPL expression was observed in LNCaP cells treated with LY-294002. The significant potentiation of LNCaP cell death by inhibition of ERK 1/2, p38, and PI3-K pathways may provide a rationale for therapeutic approach in androgen-dependent prostate cancer.